March 20 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- ANNOUNCES ITS INTENTION TO MAKE AN OFF-MARKET TAKEOVER OFFER TO ACQUIRE HEALIUS LIMITED
- OFFER WILL BE MADE BY WAY OF AN OFF-MARKET TAKEOVER OFFER BY ACL TO ACQUIRE ALL OF HEALIUS SHARES ON ISSUE
- ACL'S OFFER IS 0.74 ACL SHARES FOR EVERY 1 HEALIUS SHARE HELD
- IF ACL SUCCESSFUL IN ACQUIRING ALL OF HEALIUS SHARES ON ISSUE UNDER OFFER, HEALIUS SHAREHOLDERS WILL HOLD ABOUT 68% OF ACL
- ACL EXPECTS THAT ITS EBIT FOR FY23 WILL BE WITHIN RANGE OF A$68 MILLION AND A$74 MILLION
- MATERIAL SYNERGY POTENTIAL OF A$95 MILLION BY BRINGING COMPANIES TOGETHER
- POTENTIAL MERGED GROUP PRO FORMA FY23 EBIT OF A$361 MILLION INCLUDING EXPECTED COST SYNERGIES
(([email protected];))
March 20 (Reuters) - Australian Clinical Labs Ltd (ACL) :...
Add to My Watchlist
What is My Watchlist?